The fecal immunochemical test (FIT) is commonly used for colorectal cancer screening and positive test results require follow-up colonoscopy. However, follow-up intervals vary, which may result in neoplastic progression.
Task Force endorses multiple screening approaches for early detection of colorectal cancer, including fecal immunochemical test (FIT) screening.
2 FIT screening is commonly used worldwide 3,4 and because of its sensitivity, effectiveness, low cost, and ability to be distributed by mail, it is an increasingly common method for meeting colorectal cancer screening goals in the United States. A positive FIT result needs to be followed by a complete colon examination, typically with colonoscopy 5 ; however, recommendations for how quickly to complete follow-up differ and lack a strong evidence base. [6] [7] [8] In practice, there is marked variation in time to follow-up after a positive stool test result, which may result in neoplastic progression. Few studies have evaluated colorectal cancer outcomes associated with variation in time to follow-up. Two studies of military veterans reported no association between longer intervals from a positive test result to colonoscopy and either cancer stage or survival, but small sample sizes limited power. 9, 10 Because colorectal cancer screening theoretically affects every adult who reaches screening age and adoption of FIT screening worldwide is increasing, there is a need to provide evidence-based follow-up recommendations. The present study tested the hypothesis that longer time to colonoscopy after a positive FIT result is associated with an increased risk of any colorectal cancer and advanced-stage disease at diagnosis.
Methods

Study Population and Oversight
This study was approved by the local institutional review boards and a waiver was granted for obtaining written informed consent from study participants. This was a retrospective cohort study of Kaiser Permanente Northern California and Southern California health plan members. These integrated health care delivery organizations serve approximately 7.5 million members throughout California, and the diverse membership is similar to the region's census demographics.
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Organized Colorectal Cancer Screening Programs
The health plans initiated organized FIT outreach in 2006.
14 Each year, health plan members aged 50 to 75 years who are eligible for screening and not up-to-date with screening by other methods are mailed a FIT kit (OC FIT-CHEK, Polymedco).
Patients mail completed kits to regional laboratories where they are analyzed using OC-Sensor Diana (Polymedco; positive result, ≥100 ng/mL of hemoglobin [20 μg of hemoglobin per gram of stool]). FIT kits are also distributed in-person to patients not up-to-date at office visits or when receiving a flu shot. Patients with a positive FIT result are referred by their physician or contacted by the gastroenterology department for colonoscopy scheduling.
Study Eligibility Criteria
Members were eligible for the study if they were aged 50 to 75 years and had completed FIT screening between January 1, 2010, and October 31, 2012, for Kaiser Permanente Southern California members and January 1, 2010, and July 31, 2013, for Kaiser Permanente Northern California members. Among those with a positive FIT result, patients were excluded if they had a prior history of colorectal cancer, less than 1 year of membership after FIT screening and no record of a colonoscopy during that period, a more than 3-month gap in membership after screening, less than 1 year of membership prior to screening (to record prior out-of-system endoscopy procedures and diagnoses), a colonoscopy within 10 years or sigmoidoscopy within 5 years before FIT screening, or a colonoscopy or colorectal cancer diagnosis 1 to 7 days after their positive FIT result (because these FITs may represent diagnostic rather than screening tests).
Follow-up Time Intervals and Cancer Outcomes
The exposure was the time elapsed between a positive FIT result and subsequent colonoscopy. Time was examined as a continuous variable and in 7 intervals; the reference group was 8 to 30 days and comparison categories were 2 months (31-60 days), 3 months (61-90 days), 4-6 months (91-180 days), 7-9 months (181-272 days), 10-12 months (273-365 days), and more than 12 months (366-1751 days). The intervals were chosen to evaluate published follow-up recommendations (ie, ≤31 days [European recommendation 15 ]a n d ≤60 days [Canadian 3 and Veterans Health Administration recommendations]), to provide calendar month intervals as practical cutoffs (ie, 1, 2, 3, 4-6, 7-9, 10-12, and >12 months) , and to balance sample sizes based on outcome distributions. The primary outcomes were any colorectal adenocarcinoma diagnosed at or within 6 months after the follow-up colonoscopy, cancer by stage, advanced-stage disease, and adenomas with advanced histology (ie, tubulovillous and villous adenomas). The window for the primary outcome was defined as diagnoses at or within 6 months to account for colonoscopies that were repeated due to variables such as poor bowel preparation, incomplete examination or excision, or patient intolerance, among others; however, 96% of diagnoses Revision, procedure codes (45.21-45.23, 45.25, 45.42, 45.43, 98.04) , and Healthcare Common Procedure Coding System codes (G0105, G0121). Colorectal adenocarcinoma diagnoses and cancer stages were obtained from Kaiser Permanente cancer registries, which report to the Surveillance, Epidemiology, and End Results (SEER) Program and capture more than 99% of cancers diagnosed among members compared with manual review. Advanced-stage cancers were defined as stage III (regional lymph node involvement) or stage IV (distant metastasis) according to the American Joint Committee on Cancer staging system or, for those without such staging, as code 3 (disease in the regional lymph nodes), code 4 (regional disease with direct extension and spread to the regional lymph nodes), or code 7 (distant metastasis) according to the 2013 SEER Program Coding and Staging Manual.
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Adenomas with advanced histology were identified using Systematized Nomenclature of Medicine codes in pathology databases linked to the date of the colonoscopy examination. Validation studies confirmed high levels (>95%) of sensitivity and accuracy for capture and classification of colonoscopy examinations, adenoma diagnoses, histology, and cancers.
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Statistical Analyses
P values for differences in baseline characteristics were derivedfromχ 2 tests. Crude rates and 95% CIs were calculated as cases per 1000 patients who completed a colonoscopy. Risk analyses used multivariable logistic regression models. Odds ratios (ORs) and 95% CIs were adjusted for sex; age at FIT screening (50-54, 55-59, 60-64, 65-69, 70-75 
Results
Of 1 258 039 patients aged 50 to 75 years who completed FIT screening, 106 520 (8.5%) had a positive FIT result ( Figure 1 ). Of these, 51 patients were excluded for history of colorectal cancer, 2873 for less than 1 year of membership after FIT screening and no record of a colonoscopy during that period, 17 for a membership gap of more than 3 months after screening, 9771 for less than 1 year of membership prior to FIT screening, 10 873 for a colonoscopy within less than 10 years or sigmoidoscopy within less than 5 years before FIT screening, and 1417 for colonoscopy or colorectal cancer diagnosis within 1 to 7 days after their positive FIT. Of the remaining 81 518 patients with a positive FIT result, 70 124 (86.0% and 65.8% of those with a positive FIT result [n = 106 520]) received a follow-up colonoscopy by the end of the study period.
Characteristics of the Cohort
Of the 81 518 eligible patients with a positive FIT result, 33.3% received a colonoscopy within 30 days, 63.6% within 2 months, 74.2% within 3 months, 80.6% within 6 months, and 83.2% within 12 months; completion rates were similar in the total group of 106 520 patients who had a positive FIT result (eFigure 1 in the Supplement). Among the 70 124 patients who received a follow-up colonoscopy ( Table 2) . Baseline covariates across time-to-colonoscopy exposure groups were typically within a few percentage points (Tables 1 and 2 ), although even small differences were significant given the large sample size. Compared with no adjustment, accounting for common baseline factors (eg, age, sex, race/ethnicity, comorbidity, and prior FIT screening) moderately reduced the strength of associations (eTable 1, model 1, in the Supplement), but did not change their direction; adjustment for additional factors related to health and health care utilization slightly strengthened the associations (eTable 1, model 2, in the Supplement).
In sensitivity analyses (Table 3) , the pattern of increased OR estimates for any colorectal cancer, advanced-stage disease with examinations at 10 to 12 months and more than 12 months after FIT, or both persisted with different reference group definitions and when individuals were excluded if colonoscopy was performed more than 24 months after a positive FIT result (thereby excluding people unlikely to have a cancer, given they had not developed signs or symptoms after extended follow-up). When 20 644 originally excluded patients who had either less than 1 year of membership prior to FIT screening or were up-to-date with screening by prior endoscopy were included, risk was higher only for follow-up at more than 12 months. With 8 to 60 days and 8 to 90 days as the reference group, the risk of any colorectal cancer was also higher in the 7 to 9 months exposure group. The 1 to 7 days exposure group had a higher risk of colorectal cancer outcomes, suggesting that extremely rapid follow-up (within a week) likely represents a high-risk group. The associations between time to colonoscopy and risk of any colorectal cancer and advanced-stage disease differed somewhat across strata of age, prior FIT screening, and no preventive vaccinations in the year before FIT screening (eTable 2inSupplement); region was also an effect modifier for advanced-stage disease. However, the differences were small, with the exception of age, and significant associations persisted across all strata. For example, similar increases in risk for advanced-stage disease were found for patients with and without prior FIT screening (OR, 1.05 [95% CI 1.04-1.07] with prior FIT screening vs OR, 1.04 [95% CI 1.02-1.06] without prior FIT screening). Also, stronger associations for both any colorectal cancer and advanced-stage disease were found among older patients rather than younger patients, although significant associations were found for both groups.
Discussion
Among patients in a community-based setting with positive FIT results, there was no significant increase in risk of overall colorectal cancer or advanced colorectal cancer associated with of evidence for effectiveness. Given the lack of supporting evidence for recommendations, and the substantial difficulties for patients and clinicians to rapidly schedule and complete sedated examinations (which require time off from work, a person to accompany the patient home, and skilled personnel), 15 current US consensus guidelines offer no recommendation regarding the time interval between a positive FIT result and follow-up colonoscopy.
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Prior studies have mainly explored risk factors for different times to follow-up colonoscopy [18] [19] [20] [21] [22] [23] [24] [25] 27, [29] [30] [31] [32] and methods for improving follow-up, 26, 33, [35] [36] [37] rather than the actual consequences of different times to follow-up on cancer outcomes. An analysis of 100 veterans referred for colonoscopy after a positive FIT result reported no association between follow-up time and colorectal cancer stage. 10 A study of 231
veterans-which, due to sample-size limitations, primarily evaluated trends rather than specific time intervals-reported that each additional 30-day wait for colonoscopy after a positive FIT result was associated with an increased risk of any adenoma (OR, 1.10 [95% CI, 1.02-1.19]), but did not achieve statistical significance for advanced neoplasia (advanced adenomas or intramucosal carcinoma) or invasive cancers. 9 Both studies included single sites with predominantly male populations. A Canadian study of 246 patients with colorectal cancer reported no association between waittime and node positivity or presence of distant metastases at diagnosis. 38 A modeling study reported that, compared with colonoscopy within 2 weeks of a positive FIT result, waiting 12 months might reduce the total years of life gained from screening by an estimated 9%. 39 Although the modeling study reported a steady increase in risk between the duration of the delay and screening benefits lost, the current study only found evidence for a higher risk of overall colorectal cancer and advanced disease for colonoscopies performed more than 10 months after a positive FIT result. Therefore, although the time interval from colorectal polyp initiation to colorectal cancer is believed to span years, our study findings raise the possibility that by the time a lesion is detectable by FIT, further lesion progression might occur as soon as 6 to 12 months after a positive FIT result, although confounding remains a possible explanation for these findings. Study strengths include its large size and number of colorectal cancer outcomes; comprehensive capture of FIT and cancer results; a multi-medical center, communitybased, diverse population; validated approaches for capturing pathology data and colonoscopy examinations; histological confirmation of adenomas; validated SEER cancer registries; evaluation of a large number of possible confounding factors; and evaluation of assumptions through sensitivity analyses.
Limitations include the observational design and potential influence of unmeasured confounders, although the large number of patients allowed well-powered evaluations of a large number of possible confounding factors. Increases in risk over time were seen across all strata of assessed potential confounders, including among patients with and without prior screening, comorbidities, and health careseeking behaviors. Measures of colonoscopy quality were not available for all patients; however, a large-scale chart review in the study population demonstrated cecal intubation rates of 97.7% and adequate to excellent bowel preparations in 92.0% of examinations. 40 In addition, adenoma size was not available; thus, advanced adenomas were defined only by advanced histology.
Conclusions
Among patients with a positive fecal immunochemical test result, compared with follow-up colonoscopy at 8 to 30 days, follow-up after 10 months was associated with a higher risk of colorectal cancer and more advanced-stage disease at the time of diagnosis. Further research is needed to assess whether this relationship is causal.
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